Literature DB >> 25460828

The role of PGE2 in intestinal inflammation and tumorigenesis.

David C Montrose1, Masako Nakanishi1, Robert C Murphy2, Simona Zarini2, Jeremy P McAleer3, Anthony T Vella3, Daniel W Rosenberg4.   

Abstract

Release of the free fatty acid arachidonic acid (AA) by cytoplasmic phospholipase A2 (cPLA2) and its subsequent metabolism by the cyclooxygenase and lipoxygenase enzymes produces a broad panel of eicosanoids including prostaglandins (PGs). This study sought to investigate the roles of these mediators in experimental models of inflammation and inflammation-associated intestinal tumorigenesis. Using the dextran sodium sulfate (DSS) model of experimental colitis, we first investigated how a global reduction in eicosanoid production would impact intestinal injury by utilizing cPLA2 knockout mice. cPLA2 deletion enhanced colonic injury, reflected by increased mucosal ulceration and pro-inflammatory cytokine expression. Increased disease severity was associated with a significant reduction in the levels of several eicosanoid metabolites, including PGE2. We further assessed the precise role of PGE2 synthesis on mucosal injury and repair by utilizing mice with a genetic deletion of microsomal PGE synthase-1 (mPGES-1), the terminal synthase in the formation of inducible PGE2. DSS exposure caused more extensive acute injury as well as impaired recovery in knockout mice compared to wild-type littermates. Increased intestinal damage was associated with both reduced PGE2 levels as well as altered levels of other eicosanoids including PGD2. To determine whether this metabolic redirection impacted inflammation-associated intestinal tumorigenesis, Apc(Min/+) and Apc(Min/+):mPGES-1(-/-) mice were exposed to DSS. DSS administration caused a reduction in the number of intestinal polyps only in Apc(Min/+):mPGES-1(-/-) mice. These results demonstrate the importance of the balance of prostaglandins produced in the intestinal tract for maintaining intestinal homeostasis and impacting tumor development.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colitis; Cytosolic phosphlipase A(2); Intestine; Microsomal prostaglandin E synthase-1; Prostaglandins; Tumorigenesis

Mesh:

Substances:

Year:  2014        PMID: 25460828      PMCID: PMC4385488          DOI: 10.1016/j.prostaglandins.2014.10.002

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  55 in total

Review 1.  Regulation of cyclo-oxygenase-2.

Authors:  E Stack; R N DuBois
Journal:  Best Pract Res Clin Gastroenterol       Date:  2001-10       Impact factor: 3.043

2.  Exacerbation of inflammatory bowel disease associated with use of celecoxib.

Authors:  G F Bonner
Journal:  Am J Gastroenterol       Date:  2001-04       Impact factor: 10.864

Review 3.  Prostaglandins and ulcerative colitis.

Authors:  D S Rampton; C J Hawkey
Journal:  Gut       Date:  1984-12       Impact factor: 23.059

4.  The role of mutant Apc in the development of dysplasia and cancer in the mouse model of dextran sulfate sodium-induced colitis.

Authors:  H S Cooper; L Everley; W C Chang; G Pfeiffer; B Lee; S Murthy; M L Clapper
Journal:  Gastroenterology       Date:  2001-12       Impact factor: 22.682

5.  Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine.

Authors:  P Sharon; M Ligumsky; D Rachmilewitz; U Zor
Journal:  Gastroenterology       Date:  1978-10       Impact factor: 22.682

Review 6.  Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives.

Authors:  F Halter; A S Tarnawski; A Schmassmann; B M Peskar
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

7.  Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathione-dependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4/MyD88/NF-IL6 pathway.

Authors:  Satoshi Uematsu; Makoto Matsumoto; Kiyoshi Takeda; Shizuo Akira
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

8.  Studies on changes of colonic mucosal PGE2 levels and tissue localization in experimental colitis.

Authors:  S Yamashita
Journal:  Gastroenterol Jpn       Date:  1993-04

9.  Downregulation of CYP3A and P-glycoprotein in the secondary inflammatory response of mice with dextran sulfate sodium-induced colitis and its contribution to cyclosporine A blood concentrations.

Authors:  Shoji Kawauchi; Tsutomu Nakamura; Ikuya Miki; Jun Inoue; Tsuneo Hamaguchi; Toshihito Tanahashi; Shigeto Mizuno
Journal:  J Pharmacol Sci       Date:  2014-01-31       Impact factor: 3.337

10.  Prostanoid synthesis by cultured intestinal epithelial and mononuclear cells in inflammatory bowel disease.

Authors:  A Zifroni; A J Treves; D B Sachar; D Rachmilewitz
Journal:  Gut       Date:  1983-07       Impact factor: 23.059

View more
  34 in total

1.  Is iPLA2β a Novel Target for the Development of New Strategies to Alleviate Inflammatory Bowel Disease?

Authors:  Toni Petan; Igor Križaj
Journal:  Dig Dis Sci       Date:  2015-12       Impact factor: 3.199

Review 2.  Cytosolic phospholipase A₂: physiological function and role in disease.

Authors:  Christina C Leslie
Journal:  J Lipid Res       Date:  2015-04-02       Impact factor: 5.922

3.  Misoprostol protects mice against severe Clostridium difficile infection and promotes recovery of the gut microbiota after antibiotic perturbation.

Authors:  Joseph P Zackular; Leslie Kirk; Bruno C Trindade; Eric P Skaar; David M Aronoff
Journal:  Anaerobe       Date:  2019-06-17       Impact factor: 3.331

Review 4.  Phospholipase Signaling in Breast Cancer.

Authors:  Yu Jin Lee; Kyeong Jin Shin; Hyun-Jun Jang; Dong-Young Noh; Sung Ho Ryu; Pann-Ghill Suh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Non-cell autonomous effects of targeting inducible PGE2 synthesis during inflammation-associated colon carcinogenesis.

Authors:  Masako Nakanishi; Christine Perret; Emmanuelle J Meuillet; Daniel W Rosenberg
Journal:  Carcinogenesis       Date:  2015-01-29       Impact factor: 4.944

6.  The Anti-inflammatory Effect of Personalized Omega-3 Fatty Acid Dosing for Reducing Prostaglandin E2 in the Colonic Mucosa Is Attenuated in Obesity.

Authors:  Zora Djuric; D Kim Turgeon; Ananda Sen; Jianwei Ren; Kirk Herman; Devon Ramaswamy; Lili Zhao; Mack T Ruffin; Daniel P Normolle; William L Smith; Dean E Brenner
Journal:  Cancer Prev Res (Phila)       Date:  2017-11-13

7.  Colonoscopic-Guided Pinch Biopsies in Mice as a Useful Model for Evaluating the Roles of Host and Luminal Factors in Colonic Inflammation.

Authors:  David C Montrose; Xi K Zhou; Erin M McNally; Erika Sue; Hanhan Wang; Ryohei Nishiguchi; Akanksha Verma; Olivier Elemento; Kenneth W Simpson; Peiying Yang; Timothy Hla; Andrew J Dannenberg
Journal:  Am J Pathol       Date:  2018-09-28       Impact factor: 4.307

Review 8.  Obesity-associated cancer risk: the role of intestinal microbiota in the etiology of the host proinflammatory state.

Authors:  Zora Djuric
Journal:  Transl Res       Date:  2016-07-28       Impact factor: 7.012

9.  A New Model to Study the Role of Arachidonic Acid in Colon Cancer Pathophysiology.

Authors:  Yang-Yi Fan; Evelyn Callaway; Jennifer M Monk; Jennifer S Goldsby; Peiying Yang; Logan Vincent; Robert S Chapkin
Journal:  Cancer Prev Res (Phila)       Date:  2016-06-23

10.  Cytosolic phospholipase A2α regulates G1 progression through modulating FOXO1 activity.

Authors:  Said Movahedi Naini; Gabriel J Choukroun; James R Ryan; Dirk M Hentschel; Jagesh V Shah; Joseph V Bonventre
Journal:  FASEB J       Date:  2015-12-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.